# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Monogram Technologies (NASDAQ:MGRM) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of...
Management Anticipates That it has Sufficiently Addressed the FDA's Concerns to Mitigate the Need for a Clinical Data Reque...
Roth MKM analyst Jason Wittes initiates coverage on Monogram Technologies (NASDAQ:MGRM) with a Buy rating and announces Pric...
Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused o...
The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. The FDA informed the Company ...
Monogram Technologies (NASDAQ:MGRM) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate ...